TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38251496
Drug: Colchicine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1.5 mg on day 1 and 1 mg on day 2
Study: 38251496
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 30 mg on days 1 and 2
Study: 38251498
Drug: Mirikizumab 250
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab 250 mg induction every 4 weeks for 16 weeks, then every 8 weeks from week 16 to week 52
Study: 38251524
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg biweekly) plus maximum tolerated dose of methotrexate
Study: 38251524
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg biweekly) plus reduced-dose methotrexate
Study: 38251524
Drug: Adalimumab plus
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab plus maximum tolerated dose of methotrexate
Study: 38251524
Drug: Adalimumab plus
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab plus reduced-dose methotrexate
Study: 38251564
Drug: Tocilizumab 162
Normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 162 mg weekly subcutaneously for 12 months in combination with 8 weeks of prednisone (initial doses varied from 20 mg to 60 mg).
Study: 38251564
Drug: Tocilizumab 162
Normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 162 mg weekly subcutaneously for 12 months in combination with 8 weeks of prednisone.
Study: 38251576
Drug: Obexelimab 5
Normalized name: Obexelimab
DrugBank: Obexelimab (DB15032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obexelimab 5 mg/kg intravenously every 2 weeks for 24 weeks
Study: 38251576
Drug: Obexelimab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obexelimab treatment
Study: 38251589
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg taken orally twice a day for 12 weeks
Study: 38251590
Drug: BMS-986142 100
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986142 100 mg
Study: 38251590
Drug: BMS-986142 200
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986142 200 mg
Study: 38251601
Drug: Secukinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (300 mg subcutaneously once a week up to week 4 and every 4 weeks thereafter)
Study: 38251791
Drug: Fexuprazan 40
Normalized name: fexuprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexuprazan 40 mg once daily for 4-8 weeks
Study: 38251791
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily for 4-8 weeks
Study: 38251791
Drug: Fexuprazan 40
Normalized name: fexuprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexuprazan 40 mg
Study: 38251861
Drug: Gel (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel (control group)
Study: 38252423
Drug: Positive Airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Airway Pressure (PAP) treatment
Study: 38252549
Drug: Oral Cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Cannabidiol Treatment
Study: 38252908
Drug: Cemiplimab 350
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 350 mg intravenously once every 3 weeks for up to 2 years
Study: 38252908
Drug: mTOR inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitor and corticosteroids (prednisone 40 mg once daily, the day before and on days 1-3 of each cycle, followed by 20 mg once daily on days 4-6, then 10 mg once daily until the day before each subsequent cycle)
Study: 38253245
Drug: Omalizumab treatment
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab treatment for patients Inside Dosing Table (n=506)
Study: 38253245
Drug: Omalizumab treatment
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab treatment for patients Outside Dosing Table (n=209)
Study: 38253245
Drug: Omalizumab treatment
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab treatment for patients Insufficient Data to Recommend a Dose (n=72)
Study: 38253318
Drug: Bilateral ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound-guided suprazygomatic maxillary nerve block (5 ml of 0.37% ropivacaine)
Study: 38253338
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of RSVPreF3 OA
Study: 38253338
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of RSVPreF3 OA (first dose followed by revaccination)
Study: 38253436
Drug: HEAVY (high-load,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEAVY (high-load, full-range, supervised twice/week)
Study: 38253886
Drug: Diluted calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted calcium hydroxylapatite (CaHA; Radiesse®) administered via cannula-based subcision technique, total of 12 syringes, 1:1 dilution, across three treatment sessions
Study: 38254137
Drug: Room air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room air at a flow rate of 2 L/min.
Study: 38254147
Drug: Leap Motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leap Motion Controller® device combined with conventional therapy
Study: 38254201
Drug: Oral 5-Aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-Aminolevulinic acid (5-ALA) concurrent to radiotherapy (RT) with a maximum of eight fractions of radiodynamic therapy (RDT).
Study: 38254201
Drug: Oral 5-Aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-Aminolevulinic acid (5-ALA) concurrent to radiotherapy (RT).
Study: 38254201
Drug: 5-ALA metabolites
Normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-ALA metabolites and radiobiological markers analysis throughout the course of therapy.
Study: 38254211
Drug: Azvudine 5
Normalized name: Azvudine
DrugBank: Azvudine (DB16407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azvudine 5 mg daily for a maximum of 7 days
Study: 38254211
Drug: Placebo (five
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (five tablets daily)
Study: 38254233
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral block (TPVB) with 15 ml of 0.5% ropivacaine administered to T4 and T7 thoracic paravertebral spaces before general anaesthesia induction.
Study: 38257071
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids, dosage and duration not specified
Study: 38258329
Drug: Decitabine 20
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m² followed by cytarabine
Study: 38258563
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bolus of recombinant staphylokinase (r-SAK) before PCI
Study: 38258673
Drug: Hip-focused physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip-focused physical therapy
Study: 38258673
Drug: Spine-focused physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spine-focused physical therapy
Study: 38258677
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (6 mg)
Study: 38259250
Drug: Pelabresib (CPI-0610)
Normalized name: pelabresib
DrugBank: Pelabresib anhydrous (DB17129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelabresib (CPI-0610) 225 mg tablet QD
Study: 38259304
Drug: Rivaroxaban therapy
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban therapy
Study: 38260556
Drug: Febuxostat (XOI)
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat (XOI) treatment for 48 weeks
Study: 39541169
Drug: Baricitinib 2
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2 mg daily for 16 weeks
Study: 38261092
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RV dysfunction with RV dilation or ACP
Study: 38261313
Drug: Pralsetinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pralsetinib (400 mg once daily, orally)
Study: 38261316
Drug: Avelumab at
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab at 10 mg/kg on days 1 and 15, ramucirumab at 8 mg/kg on days 1 and 15, paclitaxel at 80 mg/m2 on days 1, 8, and 15 every 4 weeks.
Study: 38261323
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of naloxone (4 mg/0.1 mL) at 0, 2.5, 5, and 7.5 minutes
Study: 38261323
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of naloxone at 0 and 2.5 minutes
Study: 38261323
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of naloxone at 0 and 2.5 minutes (control)
Study: 38261323
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of naloxone at 0, 2.5, 5, and 7.5 minutes (test)
Study: 38261323
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of naloxone at 0 and 2.5 minutes (test)
Study: 38261390
Drug: Modified remission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified remission glucocorticoid threshold (<5.0 mg/day prednisolone)
Study: 38261392
Drug: Lupus anticoagulant
Normalized name: Lupus anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupus anticoagulant positivity at inclusion
Study: 38261392
Drug: Triple antiphospholipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiphospholipid antibody positivity
Study: 38261444
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg twice daily and Uprosertib starting at 50 mg daily (doublet cohort)
Study: 38261444
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg twice daily, Trametinib 2 mg daily, and Uprosertib 75 mg daily (triplet cohort)
Study: 38261579
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of azithromycin (20 mg/kg)
Study: 38261893
Drug: Pharmacist-led program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led program for HCV treatment
Study: 38261893
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral medications (DAAs) initiation
Study: 38261893
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of DAAs treatment
Study: 38261958
Drug: Camrelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (200 mg intravenously, day one) + Apatinib (250 mg, q.d., five continuous days per week) + Nab-paclitaxel (135 mg/m2)
Study: 38262275
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low endothelial shear stress (ESS), high ESS gradient (ESSG), and high plaque structural stress (PSS) heterogeneity index (HI)
Study: 38262275
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low ESS, high ESSG, and high PSS HI with plaque burden >70%
Study: 38262428
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g intravenous once within 12 hours following tracheal intubation
Study: 38263021
Drug: Amlodipine/benazepril 5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/benazepril 5/10 mg
Study: 38263021
Drug: Benazepril/hydrochlorothiazide 10/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril/hydrochlorothiazide 10/12.5 mg
Study: 38263053
Drug: Prehabilitation (structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehabilitation (structured exercise training, nutritional counselling/therapy, psychological support) 2-3 sessions/week for at least 4 weeks before surgery
Study: 38263321
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg orally once a day and durvalumab 1500 mg once every 3 weeks
Study: 38263486
Drug: EGFR BATs
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR BATs (anti-CD3 x anti-EGFR bispecific antibody armed T cells) in combination with radiation and temozolomide (TMZ)
Study: 38263486
Drug: EGFR BATs
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR BATs at the maximum feasible dose of 80 × 10
Study: 38263652
Drug: Intravenous iscalimab
Normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iscalimab (10 mg/kg)
Study: 38264276
Drug: 5-mcg norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mcg norepinephrine
Study: 38264276
Drug: 10-mcg norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mcg norepinephrine
Study: 38264520
Drug: Enzalutamide as
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide as first line treatment for mCRPC
Study: 38264632
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of oral psilocybin (first dose: 25 mg; second dose: 25 or 30 mg) paired with non-directive support
Study: 38264697
Drug: CURATE.AI-assisted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: CURATE.AI-assisted dose titration
Study: 38264869
Drug: Rucosopasem 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucosopasem 100 mg
Study: 38264938
Drug: Ultrasound-facilitated catheter-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-facilitated catheter-directed thrombolysis (USCDT) with mean alteplase (r-tPA) infusion duration of 10.5 hours and mean total r-tPA dose of 18.1 mg.
Study: 38265029
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (prescribed to 30.8% of children)
Study: 38265029
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic treatment (not prescribed to 69.2% of children)
Study: 38265835
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg, once daily)
Study: 38266104
Drug: Pexidartinib (CSF-1R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexidartinib (CSF-1R inhibitor)
Study: 38266154
Drug: Low-titer inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-titer inhibitor progression to high-titer inhibitor
Study: 38266332
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for anxiety and obsessive-compulsive disorders, 12 sessions
Study: 38266482
Drug: Post-trigger LH
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-trigger LH levels < 22 IU/L
Study: 38266482
Drug: Basal LH
Normalized name: LH-708
DrugBank: LH-708 (DB17636)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal LH levels < 4 IU/L
Study: 38266482
Drug: Post-trigger LH
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-trigger LH levels above 15 IU/L
Study: 38266683
Drug: Apremilast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast (20 or 30 mg BID based on weight)
Study: 38267096
Drug: CRE infection
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRE infection vs CSE infection (with treatment-related variables)
Study: 38267188
Drug: Glenzocimab 1000
Normalized name: Glenzocimab
DrugBank: Glenzocimab (DB16175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glenzocimab 1000 mg
Study: 38267243
Drug: Ferric derisomaltose
Normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferric derisomaltose infusion
Study: 38267243
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous succinate
Study: 38267245
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBM) at a dose of 7.5 J/cm²
Study: 38267330
Drug: 20-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-valent pneumococcal conjugate vaccine (PCV20)
Study: 38267330
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide vaccine (PPSV23)
Study: 38267942
Drug: Allopurinol administered
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol administered immediately after birth
Study: 38268156
Drug: Metformin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (0.5 g three times per day)
Study: 38268157
Drug: Secukinumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (150 mg to 300 mg dose escalation)
Study: 38268221
Drug: Maternal vaginal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal vaginal and rectal microbiomes during the last trimester
Study: 38268752
Drug: Batoclimab 680
Normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batoclimab 680 mg QW for 12 weeks
Study: 38268752
Drug: Batoclimab 340
Normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batoclimab 340 mg QW for 12 weeks
Study: 38268752
Drug: Batoclimab 340
Normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batoclimab 340 mg QW or Q2W for maintenance
Study: 38269045
Drug: Customized silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized silicone digital orthoses plus specialized nurse-administered foot care
Study: 38269045
Drug: Specialized nurse-administered
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized nurse-administered foot care (Control Group)
Study: 38269046
Drug: Pharmaceutical consultation
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical consultation at hospital
Study: 38269046
Drug: Pharmaceutical consultation
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical consultation at community pharmacy
Study: 38270814
Drug: Chemotherapy, radiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy, radiotherapy, or immunotherapy
Study: 38270822
Drug: Navitoclax 150
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax 150 mg daily plus Sorafenib 400 mg twice daily
Study: 38271019
Drug: TranS-C group
Normalized name: meningococcal group C polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TranS-C group treatment
Study: 38271308
Drug: Oral Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Assessment Guide (OAG) assessment
Study: 38271308
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of oral care
Study: 38272050
Drug: Individualised short-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised short-course antibiotic treatment (≤7 days, as short as 3-5 days)
Study: 38272050
Drug: Short-course treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course treatment
Study: 38272046
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (2 g/kg, single dose)
Study: 38272046
Drug: Methylprednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (10 mg/kg per day for 3 consecutive days)
Study: 38272046
Drug: Tocilizumab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (12 mg/kg for patients <30 kg; 8 mg/kg for patients ≥30 kg, max 800 mg)
Study: 38272046
Drug: Anakinra (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (2 mg/kg once per day for patients ≥10 kg)
Study: 38272046
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no additional treatments)
Study: 38272373
Drug: Dupilumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab treatment in patients with biallelic pathogenic FLG variants
Study: 38272373
Drug: Dupilumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab treatment in patients with monoallelic pathogenic FLG variants or wild-type alleles
Study: 38272375
Drug: dupilumab 100/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: dupilumab 100/200 mg by body weight or volume-matched placebo every 2 weeks for 52 weeks
Study: 38272383
Drug: PPOS protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPOS protocol (Medroxyprogesterone 10 mg daily from start of ovarian stimulation until ovulation trigger)
Study: 38272383
Drug: Antagonist protocol
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist protocol (Antagonist 0.25 mg daily from the sixth day of ovarian stimulation until ovulation trigger)